Skip to main content
Erschienen in: Indian Journal of Surgical Oncology 1/2019

30.11.2018 | Original Article

Prognostic Utility of Cyclin D1 in Invasive Breast Carcinoma

verfasst von: Tamanna Parvin, Chhanda Das, Manoj Choudhury, Bitan Kumar Chattopadhyay, Madhumita Mukhopadhyay

Erschienen in: Indian Journal of Surgical Oncology | Ausgabe 1/2019

Einloggen, um Zugang zu erhalten

Abstract

Invasive breast carcinoma is the most common cancer among women worldwide. Increase in early detection of breast carcinoma by different diagnostic modalities led to decrease in cancer-related mortality and morbidity. Multiple factors and genes are implicated in breast cancer pathogenesis. Cyclin D1 is an important cell cycle regulatory protein involved in carcinogenesis of various human cancers including breast cancer. Aims of the present study were to evaluate the prognostic importance of cyclin D1 expression in invasive breast carcinoma and its correlation with other prognostic and predictive factors. Patients undergoing mastectomy for breast carcinoma were selected from January 2016 to June 2017 in a tertiary care hospital. Clinical history including demographic parameters was collected in the study pro forma. Immunohistochemical staining for ER, PgR, HER2 and cyclin D1 was performed on all cases. The clinicopathological parameters like age, tumour size, histologic grade, histological type, lymphovascular invasion, axillary lymph node metastasis, ER, PgR and HER2 status were compared and correlated with cyclin D1 expression. Cyclin D1 expression found in 60% cases of breast carcinoma. Expression of cyclin D1 showed a highly significant correlation with histological grade (p = 0.000). Cyclin D1 expression showed significant correlation (p = 0.000) with molecular subtypes. There was also significant correlation between cyclin D1 expression and ER (p = 0.000) and PgR (p = 0.010) status. This study revealed significant cyclin D1 expression in low grade, well-differentiated breast cancer. Therefore, we found cyclin D1 as a favourable prognostic marker in breast carcinoma.
Literatur
1.
Zurück zum Zitat Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M et al (2014) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136(5):E359–E386CrossRefPubMed Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M et al (2014) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136(5):E359–E386CrossRefPubMed
2.
Zurück zum Zitat Malvia S, Bagadi SA, Dubey US, Saxena S (2017) Epidemiology of breast cancer in Indian women. Asia Pac J Clin Oncol 13(4):289–295CrossRefPubMed Malvia S, Bagadi SA, Dubey US, Saxena S (2017) Epidemiology of breast cancer in Indian women. Asia Pac J Clin Oncol 13(4):289–295CrossRefPubMed
3.
Zurück zum Zitat Hoda SA (2014) Invasive ductal carcinoma: assessment of prognosis with morphologic and biologic markers. In: Rosen PP (ed) Rosen’s breast pathology, 4th edn. Lippincott Williams & Wilkins, Philadelphia, USA, p 413 Hoda SA (2014) Invasive ductal carcinoma: assessment of prognosis with morphologic and biologic markers. In: Rosen PP (ed) Rosen’s breast pathology, 4th edn. Lippincott Williams & Wilkins, Philadelphia, USA, p 413
5.
Zurück zum Zitat Sutherland RL, Musgrove EA (2002) Cyclin D1 and mammary carcinoma: new insights from transgenic mouse models. Breast Cancer Res 4(1):14–17CrossRefPubMed Sutherland RL, Musgrove EA (2002) Cyclin D1 and mammary carcinoma: new insights from transgenic mouse models. Breast Cancer Res 4(1):14–17CrossRefPubMed
6.
Zurück zum Zitat Abraham RT, Vanarsdale T, Shields DV, Lee NV, Koehler M, Arndt K (2014) Braking the cycle: inhibition of the cyclin D-Cdk4/6 pathway in breast cancer. Cancer Res 74(19 Supplement):SY34–SY03CrossRef Abraham RT, Vanarsdale T, Shields DV, Lee NV, Koehler M, Arndt K (2014) Braking the cycle: inhibition of the cyclin D-Cdk4/6 pathway in breast cancer. Cancer Res 74(19 Supplement):SY34–SY03CrossRef
7.
Zurück zum Zitat Dickson MA (2014) Molecular pathways: CDK4 inhibitors for cancer therapy. Clin Cancer Res 20(13):3379–3383CrossRefPubMed Dickson MA (2014) Molecular pathways: CDK4 inhibitors for cancer therapy. Clin Cancer Res 20(13):3379–3383CrossRefPubMed
8.
Zurück zum Zitat Eeckhoute J (2006) A cell-type-specific transcriptional network required for estrogen regulation of cyclin D1 and cell cycle progression in breast cancer. Genes Dev 20(18):2513–2526CrossRefPubMedPubMedCentral Eeckhoute J (2006) A cell-type-specific transcriptional network required for estrogen regulation of cyclin D1 and cell cycle progression in breast cancer. Genes Dev 20(18):2513–2526CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Arnold A, Papanikolaou A (2005) Cyclin D1 in breast cancer pathogenesis. J Clin Oncol 23(18):4215–4224CrossRefPubMed Arnold A, Papanikolaou A (2005) Cyclin D1 in breast cancer pathogenesis. J Clin Oncol 23(18):4215–4224CrossRefPubMed
10.
Zurück zum Zitat Peurala E, Koivunen P, Haapasaari K-M, Bloigu R, Jukkola-Vuorinen A (2013) The prognostic significance and value of cyclin D1, CDK4 and p16 in human breast cancer. Breast Cancer Res 15(1):R5CrossRefPubMedPubMedCentral Peurala E, Koivunen P, Haapasaari K-M, Bloigu R, Jukkola-Vuorinen A (2013) The prognostic significance and value of cyclin D1, CDK4 and p16 in human breast cancer. Breast Cancer Res 15(1):R5CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thürlimann B et al (2013) Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol 24(9):2206–2223CrossRefPubMedPubMedCentral Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thürlimann B et al (2013) Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol 24(9):2206–2223CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat Hammond M, Hayes D, Dowsett M, Allred D, Hagerty K, Badve S et al (2010) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Arch Pathol Lab Med 134(7):48–72 Hammond M, Hayes D, Dowsett M, Allred D, Hagerty K, Badve S et al (2010) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Arch Pathol Lab Med 134(7):48–72
13.
Zurück zum Zitat Allred DC (2008) Problems and solutions in the evaluation of hormone receptors in breast cancer. J Clin Oncol 26(15):2433–2435CrossRefPubMed Allred DC (2008) Problems and solutions in the evaluation of hormone receptors in breast cancer. J Clin Oncol 26(15):2433–2435CrossRefPubMed
14.
Zurück zum Zitat Wolff A, Hammond M, Hicks D, Dowsett M, McShane L, Allison K et al (2014) Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update. Arch Pathol Lab Med 138(2):241–256CrossRefPubMed Wolff A, Hammond M, Hicks D, Dowsett M, McShane L, Allison K et al (2014) Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update. Arch Pathol Lab Med 138(2):241–256CrossRefPubMed
15.
Zurück zum Zitat Reis-Filho JS, Savage K, Lambros MBK, James M, Steele D, Jones RL, Dowsett M (2006) Cyclin D1 protein overexpression and CCND1 amplification in breast carcinomas: an immunohistochemical and chromogenic in situ hybridisation analysis. Mod Pathol 19(7):999–1009CrossRefPubMed Reis-Filho JS, Savage K, Lambros MBK, James M, Steele D, Jones RL, Dowsett M (2006) Cyclin D1 protein overexpression and CCND1 amplification in breast carcinomas: an immunohistochemical and chromogenic in situ hybridisation analysis. Mod Pathol 19(7):999–1009CrossRefPubMed
16.
Zurück zum Zitat Khemka A, Chakrabarti N, Shah S, Patel V (2008) Palpable breast lumps: fine-needle aspiration cytology versus histopathology: a correlation of diagnostic accuracy. Int J Surg 18(1) Khemka A, Chakrabarti N, Shah S, Patel V (2008) Palpable breast lumps: fine-needle aspiration cytology versus histopathology: a correlation of diagnostic accuracy. Int J Surg 18(1)
17.
Zurück zum Zitat Ahmad Z, Khurshid A, Qureshi A, Idress R, Asghar N, Kayani N (2009) Breast carcinoma grading, estimation of tumor size, axillary lymph node status, staging, and Nottingham prognostic index scoring on mastectomy specimens. Indian J Pathol Microbiol 52(4):477–481CrossRefPubMed Ahmad Z, Khurshid A, Qureshi A, Idress R, Asghar N, Kayani N (2009) Breast carcinoma grading, estimation of tumor size, axillary lymph node status, staging, and Nottingham prognostic index scoring on mastectomy specimens. Indian J Pathol Microbiol 52(4):477–481CrossRefPubMed
18.
Zurück zum Zitat Makki J (2015) Diversity of breast carcinoma: histological subtypes and clinical relevance. Clin Med Insights Pathol 8:23–31PubMedPubMedCentral Makki J (2015) Diversity of breast carcinoma: histological subtypes and clinical relevance. Clin Med Insights Pathol 8:23–31PubMedPubMedCentral
19.
Zurück zum Zitat Ravikumar G, Ananthamurthy A (2014) Cyclin D1 expression in ductal carcinoma of the breast and its correlation with other prognostic parameters. J Can Res Ther 10(3):671–675 Ravikumar G, Ananthamurthy A (2014) Cyclin D1 expression in ductal carcinoma of the breast and its correlation with other prognostic parameters. J Can Res Ther 10(3):671–675
20.
Zurück zum Zitat Rakha EA, Martin S, Lee AHS, Morgan D, Pharoah PDP, Hodi Z, Macmillan D, Ellis IO (2011) The prognostic significance of lymphovascular invasion in invasive breast carcinoma. Cancer 118(15):3670–3680CrossRefPubMed Rakha EA, Martin S, Lee AHS, Morgan D, Pharoah PDP, Hodi Z, Macmillan D, Ellis IO (2011) The prognostic significance of lymphovascular invasion in invasive breast carcinoma. Cancer 118(15):3670–3680CrossRefPubMed
21.
Zurück zum Zitat Kim M-J, Ro JY, Ahn S-H, Kim HH, Kim S-B, Gong G (2006) Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes. Hum Pathol 37(9):1217–1226CrossRefPubMed Kim M-J, Ro JY, Ahn S-H, Kim HH, Kim S-B, Gong G (2006) Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes. Hum Pathol 37(9):1217–1226CrossRefPubMed
23.
Zurück zum Zitat Sutherland RL, Musgrove EA (2004) Cyclins and breast cancer. J Mammary Gland Biol Neoplasia 9(1):95–104CrossRefPubMed Sutherland RL, Musgrove EA (2004) Cyclins and breast cancer. J Mammary Gland Biol Neoplasia 9(1):95–104CrossRefPubMed
24.
Zurück zum Zitat Hwang TS, Han HS, Hong YC, Lee HJ, Paik N-S (2003) Prognostic value of combined analysis of cyclin D1 and estrogen receptor status in breast cancer patients. Pathol Int 53(2):74–80CrossRefPubMed Hwang TS, Han HS, Hong YC, Lee HJ, Paik N-S (2003) Prognostic value of combined analysis of cyclin D1 and estrogen receptor status in breast cancer patients. Pathol Int 53(2):74–80CrossRefPubMed
25.
Zurück zum Zitat Chung J, Noh H, Park KH, Choi E, Han A (2014) Longer survival in patients with breast cancer with cyclin D1 over-expression after tumor recurrence: longer, but occupied with disease. J Breast Cancer 17(1):47–53CrossRefPubMedPubMedCentral Chung J, Noh H, Park KH, Choi E, Han A (2014) Longer survival in patients with breast cancer with cyclin D1 over-expression after tumor recurrence: longer, but occupied with disease. J Breast Cancer 17(1):47–53CrossRefPubMedPubMedCentral
26.
Zurück zum Zitat El-Maqsoud NMRA, Moatasem M (2010) Significance of Cyclin D1 overexpression and amplification in ductal hyperplasia, carcinoma in situ and invasive carcinoma in Egyptian female breast. Int J Cancer Res 6:202–219CrossRef El-Maqsoud NMRA, Moatasem M (2010) Significance of Cyclin D1 overexpression and amplification in ductal hyperplasia, carcinoma in situ and invasive carcinoma in Egyptian female breast. Int J Cancer Res 6:202–219CrossRef
27.
Zurück zum Zitat Guo L, Liu S, Jakulin A, Yilamu D, Wang B, Yan J (2015) Positive expression of cyclin D1 is an indicator for the evaluation of the prognosis of breast cancer. Int J Clin Exp Med 8(10):18656–18664PubMedPubMedCentral Guo L, Liu S, Jakulin A, Yilamu D, Wang B, Yan J (2015) Positive expression of cyclin D1 is an indicator for the evaluation of the prognosis of breast cancer. Int J Clin Exp Med 8(10):18656–18664PubMedPubMedCentral
29.
Zurück zum Zitat Lee A, Park WC, Yim HW, Lee MA, Park G, Lee KY (2007) Expression of c-erbB2, cyclin D1 and estrogen receptor and their clinical implications in the invasive ductal carcinoma of the breast. Jpn J Clin Oncol 37:708–714CrossRefPubMed Lee A, Park WC, Yim HW, Lee MA, Park G, Lee KY (2007) Expression of c-erbB2, cyclin D1 and estrogen receptor and their clinical implications in the invasive ductal carcinoma of the breast. Jpn J Clin Oncol 37:708–714CrossRefPubMed
30.
Zurück zum Zitat Umekita Y, Ohi Y, Sagara Y, Yoshida H (2002) Overexpression of cyclinD1 predicts for poor prognosis in estrogen receptor-negative breast cancer patients. Int J Cancer 98(3):415–418CrossRefPubMed Umekita Y, Ohi Y, Sagara Y, Yoshida H (2002) Overexpression of cyclinD1 predicts for poor prognosis in estrogen receptor-negative breast cancer patients. Int J Cancer 98(3):415–418CrossRefPubMed
31.
Zurück zum Zitat Stendahl M, Kronblad Å, Rydén L, Emdin S, Bengtsson NO, Landberg G (2004) Cyclin D1 overexpression is a negative predictive factor for tamoxifen response in postmenopausal breast cancer patients. Br J Cancer 90(10):1942–1948CrossRefPubMedPubMedCentral Stendahl M, Kronblad Å, Rydén L, Emdin S, Bengtsson NO, Landberg G (2004) Cyclin D1 overexpression is a negative predictive factor for tamoxifen response in postmenopausal breast cancer patients. Br J Cancer 90(10):1942–1948CrossRefPubMedPubMedCentral
Metadaten
Titel
Prognostic Utility of Cyclin D1 in Invasive Breast Carcinoma
verfasst von
Tamanna Parvin
Chhanda Das
Manoj Choudhury
Bitan Kumar Chattopadhyay
Madhumita Mukhopadhyay
Publikationsdatum
30.11.2018
Verlag
Springer India
Erschienen in
Indian Journal of Surgical Oncology / Ausgabe 1/2019
Print ISSN: 0975-7651
Elektronische ISSN: 0976-6952
DOI
https://doi.org/10.1007/s13193-018-0839-2

Weitere Artikel der Ausgabe 1/2019

Indian Journal of Surgical Oncology 1/2019 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

CME: 2 Punkte

Prof. Dr. med. Gregor Antoniadis Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

CME: 2 Punkte

Dr. med. Benjamin Meyknecht, PD Dr. med. Oliver Pieske Das Webinar S2e-Leitlinie „Distale Radiusfraktur“ beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

CME: 2 Punkte

Dr. med. Mihailo Andric
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.